...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer
【24h】

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer

机译：食管癌明确放化疗期间和之后患者报告的结局

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Limited data describe patient-reported outcomes (PROs) of localised oesophageal cancer treated with definitive chemoradiotherapy(CRT). The phase 2/3 SCOPE-1 trial assessed the effectiveness of CRT±cetuximab. The trial for the first time provided an opportunity to describe PROs from a multi-centre group of patients treated with CRT that are presented here. Methods: Patients undergoing CRT±cetuximab within the SCOPE-1 trial (258 patients from 36 UK centres) completed generic-, disease- and treatment-specific health-related quality of life (HRQL) questionnaires (EORTC QLQ-C30, QLQ-OES18, Dermatology Life-Quality Index (DLQI)) at baseline and at 7, 13, 24, 52 and 104 weeks. Mean EORTC functional scale scores (>15 point change significant), DLQI scores (>4 point change significant) and proportions of patients (>15% significant) with ‘minimal' or ‘severe' symptoms are presented. Results: Questionnaire response rates were good. At baseline, EORTC functional scores were high (>75%) and few symptoms were reported except for severe problems with fatigue, insomnia and eating-related symptoms (e.g., appetite loss, dysphagia, dry mouth) in both groups(>15%). Functional aspects of health deteriorated and symptoms increased with treatment and by week 13 global quality of life, physical, role and social function significantly deteriorated and more problems with fatigue, dyspnoea, appetite loss and trouble with taste were reported. Recovery occurred by 6 months (except severe fatigue and insomnia in >15% of patients) and maintained at follow-up with no differences between groups. Conclusions: CRT for localised oesophageal cancer has a significant detrimental impact on many aspects of HRQL; however, recovery is achieved by 6 months and maintained with the exception of persisting problems with severe fatigue and insomnia. The data suggest that the HRQL recovery after definitive CRT is quicker, and there is little lasting deficit compared with treatment including surgery. These data need to be compared with HRQL data from studies evaluating treatments including surgery for oesophageal cancer.
机译：背景：有限的数据描述了用定性放化疗治疗的局部食管癌患者报告的结局（PROs）。 2/3期SCOPE-1试验评估了CRT±西妥昔单抗的有效性。首次进行的临床试验为描述多中心接受CRT治疗的患者中的PRO提供了机会。方法：在SCOPE-1试验中接受CRT±西妥昔单抗治疗的患者（来自36个英国中心的258名患者）完成了针对一般，疾病和治疗的健康相关生活质量（HRQL）问卷（EORTC QLQ-C30，QLQ-OES18） ，以及基线，第7、13、24、52和104周时的皮肤病生活质量指数（DLQI）。呈现平均EORTC功能量表评分（> 15分变化显着），DLQI评分（> 4分变化显着）和出现“最小”或“严重”症状的患者比例（> 15％显着）。结果：问卷调查答复率良好。在基线时，两组的EORTC功能评分均很高（> 75％），几乎没有报道的症状，除了疲劳，失眠和饮食相关症状（例如食欲不振，吞咽困难，口干）的严重问题（> 15％） 。随着治疗，健康的功能方面恶化，症状增加，到第13周，全球生活质量，身体，角色和社会功能显着恶化，并报告了更多的疲劳，呼吸困难，食欲不振和味觉问题。康复时间为6个月（除了严重疲劳和失眠的患者超过15％），并在随访中保持不变，各组之间无差异。结论：局部食管癌的CRT对HRQL的许多方面具有重大不利影响。但是，除了持续存在的严重疲劳和失眠问题外，恢复时间可维持6个月。数据表明，确定性CRT后HRQL恢复更快，并且与包括手术在内的治疗相比，持久性缺乏几乎没有。这些数据需要与评估包括食道癌手术在内的治疗方法的研究的HRQL数据进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号